NBT Analytics

NBT Analytics operates at the intersection of neurotechnology, analytics, and biopharma. Its stated focus is measuring how drugs affect brain activity, particularly in clinical-trial contexts. The listed offering spans EEG signal preprocessing, analysis of biomarkers across temporal, spatial, and spectral domains, development of integrated drug-specific EEG indices, and consultancy. This combination suggests a specialist service and analytics provider rather than a broad drug developer or general-purpose data platform. Its potential differentiation lies in connecting EEG data preparation and biomarker interpretation with indices intended to quantify and classify drug effects. The company is based in Amsterdam and is described as having 1–10 employees, consistent with a small specialist operation. No distinct peer companies are identified in the available profile, so a defensible named-competitor comparison or relative market-share assessment is not possible.

NBT Analytics was founded in 2015 and has a recorded early-stage financing history comprising two pre-seed rounds: one dated Jan 1, 2016 with ACE Incubator as lead investor, followed by one dated Apr 26, 2018 with NLC as lead investor. The company’s described capabilities cover several steps in EEG-based drug analysis: signal preprocessing, biomarker assessment across temporal, spatial, and spectral domains, development of drug-specific indices, and consulting for clinical research and drug development. The stated employee range is 1–10. An undated hiring notice mentions technology upgrades and a master’s thesis opportunity that could lead to full-time employment, indicating possible technical development and a talent pipeline, but not a completed upgrade or measurable headcount growth. With no newer dated milestones, revenue figures, or later financing details available, the company’s trajectory beyond its 2018 round remains difficult to establish.